phosphorylcholine has been researched along with Breast Cancer in 83 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the efficacy and toxicity of perifosine in patients with metastatic breast cancer patients after up to 2 lines of prior chemotherapy for advanced disease." | 9.13 | A Phase 2 study of perifosine in advanced or metastatic breast cancer. ( Clemons, M; Crump, RM; Dancey, JE; Dent, S; Hedley, D; Leighl, NB; Moore, MJ; Pond, GR; Tozer, R; Vandenberg, TA; Warr, DG, 2008) |
| "6% Miltefosine solution is confirmed as an effective palliative treatment option for cutaneous metastases from breast cancer." | 9.09 | Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. ( David, M; Hardy, J; Houston, S; Leonard, R; Mansi, J; Simmonds, P; van Tienhoven, G, 2001) |
| "Miltefosine, either used alone or in conjunction with other therapies for distant metastases, is an effective and tolerable local treatment for cutaneous breast cancer." | 9.09 | Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma. ( Clive, S; Gardiner, J; Leonard, RC, 1999) |
| "Dysregulated choline metabolism is a well-known feature of breast cancer, but the underlying mechanisms are not fully understood." | 7.80 | Interplay of choline metabolites and genes in patient-derived breast cancer xenografts. ( Bathen, TF; Borgan, E; Børresen-Dale, AL; Engebraaten, O; Gribbestad, IS; Grinde, MT; Kristian, A; Marangoni, E; Moestue, SA; Mælandsmo, GM; Rødland, EA; Sitter, B; Skrbo, N; Sørlie, T, 2014) |
| "This study describes the molecular signaling involved in the different cell death modes of triple-negative breast cancer cells induced by hexadecylphosphocholine (HePC/miltefosine), a clinically relevant anticancer alkylphosphocholine." | 7.74 | Distinctive molecular signaling in triple-negative breast cancer cell death triggered by hexadecylphosphocholine (miltefosine). ( Chakrabandhu, K; Huault, S; Hueber, AO, 2008) |
| "Choline metabolism in breast cancer cells and tumors has been investigated by multinuclear NMR in order to provide the biochemical basis for the presence of high phosphocholine in breast carcinoma relative to benign breast tumors and normal breast tissue." | 7.70 | Choline metabolism in breast cancer; 2H-, 13C- and 31P-NMR studies of cells and tumors. ( Bendel, P; Degani, H; Katz-Brull, R; Margalit, R, 1998) |
| "31P- and 13C-NMR were used to determine the kinetics of choline and ethanolamine incorporation in T47D clone 11 human breast cancer cells grown as large (300 microns) spheroids." | 7.68 | Lipid metabolism in large T47D human breast cancer spheroids: 31P- and 13C-NMR studies of choline and ethanolamine uptake. ( Degani, H; Ronen, SM; Rushkin, E, 1992) |
| "31P and 13C-NMR were used to determine the kinetics of choline and ethanolamine incorporation in T47D clone 11 human breast cancer cells grown as small (150 microns) spheroids." | 7.68 | Lipid metabolism in T47D human breast cancer cells: 31P and 13C-NMR studies of choline and ethanolamine uptake. ( Degani, H; Ronen, SM; Rushkin, E, 1991) |
| "The effects of 17 beta-estradiol treatment versus tamoxifen on the metabolism of human breast cancer T47D-clone 11 cells were studied by noninvasive 31P and 13C nuclear magnetic resonance techniques." | 7.67 | Metabolic studies of estrogen- and tamoxifen-treated human breast cancer cells by nuclear magnetic resonance spectroscopy. ( Degani, H; Neeman, M, 1989) |
| "Miltefosine therapy was discontinued in two patients due to nausea and in one patient due to skin toxicity." | 6.69 | Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients. ( Bontenbal, M; Planting, AS; Seynaeve, C; Sindermann, H; Smorenburg, CH; Verweij, J, 2000) |
| "Miltefosine was selected because of its efficacy in breast cancer models." | 6.69 | Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer. ( Beijnen, JH; Mandjes, IA; Sindermann, H; ten Bokkel Huinink, WW; Terwogt, JM, 1999) |
| "Perifosine is an anticancer alkylphospholipid used in clinical trials." | 5.38 | Metabolic consequences of treatment with AKT inhibitor perifosine in breast cancer cells. ( Ronen, SM; Su, JS; Woods, SM, 2012) |
| "Endocrine resistance in breast cancer remains a major clinical problem and is caused by crosstalk mechanisms of growth factor receptor cascades, such as the erbB and PI3K/AKT pathways." | 5.38 | Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells. ( Block, M; Emons, G; Fister, S; Gründker, C; Günthert, AR; Hemmerlein, B; Kubin, J; Mueller, MD; Wilkens, L, 2012) |
| "To determine the efficacy and toxicity of perifosine in patients with metastatic breast cancer patients after up to 2 lines of prior chemotherapy for advanced disease." | 5.13 | A Phase 2 study of perifosine in advanced or metastatic breast cancer. ( Clemons, M; Crump, RM; Dancey, JE; Dent, S; Hedley, D; Leighl, NB; Moore, MJ; Pond, GR; Tozer, R; Vandenberg, TA; Warr, DG, 2008) |
| "6% Miltefosine solution is confirmed as an effective palliative treatment option for cutaneous metastases from breast cancer." | 5.09 | Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. ( David, M; Hardy, J; Houston, S; Leonard, R; Mansi, J; Simmonds, P; van Tienhoven, G, 2001) |
| "Miltefosine, either used alone or in conjunction with other therapies for distant metastases, is an effective and tolerable local treatment for cutaneous breast cancer." | 5.09 | Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma. ( Clive, S; Gardiner, J; Leonard, RC, 1999) |
| " Basal-like and luminal-like breast cancer xenografts were treated with the dual PI3K/mTOR inhibitor BEZ235, and the impact of treatment on the concentration of phosphocholine, glycerophosphocholine, phosphoethanolamine and glycerophosphoethanolamine was evaluated." | 3.80 | Quantitative (31)P HR-MAS MR spectroscopy for detection of response to PI3K/mTOR inhibition in breast cancer xenografts. ( Bathen, TF; Engebråten, O; Esmaeili, M; Gribbestad, IS; Moestue, SA; Mælandsmo, GM, 2014) |
| "Dysregulated choline metabolism is a well-known feature of breast cancer, but the underlying mechanisms are not fully understood." | 3.80 | Interplay of choline metabolites and genes in patient-derived breast cancer xenografts. ( Bathen, TF; Borgan, E; Børresen-Dale, AL; Engebraaten, O; Gribbestad, IS; Grinde, MT; Kristian, A; Marangoni, E; Moestue, SA; Mælandsmo, GM; Rødland, EA; Sitter, B; Skrbo, N; Sørlie, T, 2014) |
| " Upon ARID1A knockdown, MCF7 breast cancer cells and primary MRC5 cells exhibited a significantly increased sensitivity towards the AKT-inhibitors MK-2206 and perifosine, as well as the PI3K-inhibitor buparlisib." | 3.80 | Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition. ( Dedes, KJ; Fink, D; Gutsche, K; Imesch, P; Samartzis, EP; Stucki, M, 2014) |
| "This study determined that in the MCF-7 breast cancer model inhibition of Hsp90 by 17-AAG results in a significant MRS-detectable increase in choline, PC and GPC, which is likely due to an increase in choline transport into the cell and phospholipase activation." | 3.76 | 17-allyamino-17-demethoxygeldanamycin treatment results in a magnetic resonance spectroscopy-detectable elevation in choline-containing metabolites associated with increased expression of choline transporter SLC44A1 and phospholipase A2. ( Brandes, AH; Ronen, SM; Ward, CS, 2010) |
| "This study describes the molecular signaling involved in the different cell death modes of triple-negative breast cancer cells induced by hexadecylphosphocholine (HePC/miltefosine), a clinically relevant anticancer alkylphosphocholine." | 3.74 | Distinctive molecular signaling in triple-negative breast cancer cell death triggered by hexadecylphosphocholine (miltefosine). ( Chakrabandhu, K; Huault, S; Hueber, AO, 2008) |
| " Human HT29 (colon) and MDA-MB-231 (breast) carcinoma cells were examined by proton (1H) and phosphorus (31P) magnetic resonance spectroscopy (MRS) before and after treatment with MN58b both in culture and in xenografts." | 3.73 | Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. ( Al-Saffar, NM; Chung, YL; Griffiths, JR; Jackson, LE; Judson, IR; Lacal, JC; Leach, MO; Madhu, B; Ramírez de Molina, A; Troy, H; Workman, P, 2006) |
| "Miltefosine (hexadecylphosphocholine) is used for topical treatment of breast cancers." | 3.71 | MDR1 causes resistance to the antitumour drug miltefosine. ( Grunicke, H; Hofmann, J; Liu, R; Lu, P; Pietro, AD; Rybczynska, M; Sharom, FJ; Spitaler, M; Steinfels, E, 2001) |
| "Choline metabolism in breast cancer cells and tumors has been investigated by multinuclear NMR in order to provide the biochemical basis for the presence of high phosphocholine in breast carcinoma relative to benign breast tumors and normal breast tissue." | 3.70 | Choline metabolism in breast cancer; 2H-, 13C- and 31P-NMR studies of cells and tumors. ( Bendel, P; Degani, H; Katz-Brull, R; Margalit, R, 1998) |
| "31P- and 13C-NMR were used to determine the kinetics of choline and ethanolamine incorporation in T47D clone 11 human breast cancer cells grown as large (300 microns) spheroids." | 3.68 | Lipid metabolism in large T47D human breast cancer spheroids: 31P- and 13C-NMR studies of choline and ethanolamine uptake. ( Degani, H; Ronen, SM; Rushkin, E, 1992) |
| "31P and 13C-NMR were used to determine the kinetics of choline and ethanolamine incorporation in T47D clone 11 human breast cancer cells grown as small (150 microns) spheroids." | 3.68 | Lipid metabolism in T47D human breast cancer cells: 31P and 13C-NMR studies of choline and ethanolamine uptake. ( Degani, H; Ronen, SM; Rushkin, E, 1991) |
| "The effects of 17 beta-estradiol treatment versus tamoxifen on the metabolism of human breast cancer T47D-clone 11 cells were studied by noninvasive 31P and 13C nuclear magnetic resonance techniques." | 3.67 | Metabolic studies of estrogen- and tamoxifen-treated human breast cancer cells by nuclear magnetic resonance spectroscopy. ( Degani, H; Neeman, M, 1989) |
| "Miltefosine therapy was discontinued in two patients due to nausea and in one patient due to skin toxicity." | 2.69 | Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients. ( Bontenbal, M; Planting, AS; Seynaeve, C; Sindermann, H; Smorenburg, CH; Verweij, J, 2000) |
| "Miltefosine was selected because of its efficacy in breast cancer models." | 2.69 | Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer. ( Beijnen, JH; Mandjes, IA; Sindermann, H; ten Bokkel Huinink, WW; Terwogt, JM, 1999) |
| "The experience of treating cancer over the past several decades overwhelmingly demonstrates that the disease continues to evade the vast array of drugs and treatment modalities available in the twenty-first century." | 2.42 | Choline phospholipid metabolism: a target in cancer cells? ( Ackerstaff, E; Bhujwalla, ZM; Glunde, K, 2003) |
| "Both breast and pancreatic cancer cells showed higher PE compared with their nonmalignant counterparts." | 1.48 | Molecular causes of elevated phosphoethanolamine in breast and pancreatic cancer cells. ( Bhujwalla, ZM; Glunde, K; Krishnamachary, B; Shah, T; Wijnen, JP; Wildes, F, 2018) |
| "Most tumors circumvent telomere-length imposed replicative limits through expression of telomerase, the reverse transcriptase that maintains telomere length." | 1.42 | Perifosine as a potential novel anti-telomerase therapy. ( Friedman, DR; Hagiopian, MM; Holohan, B; Huang, E; Lai, TP; Shay, JW; Wright, WE, 2015) |
| "Triple negative breast cancers express receptors for gonadotropin-releasing hormone (GnRH) in more than 50% of the cases, which can be targeted with peptidic analogs of GnRH, such as triptorelin." | 1.42 | Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC). ( Buchholz, S; Engel, JB; Kwok, CW; Ortmann, O; Seitz, S; Treeck, O, 2015) |
| "Most in vivo MRS studies on breast cancer rely upon estimations of total choline (tCHO)." | 1.42 | Proof-of-the-Concept Study on Mathematically Optimized Magnetic Resonance Spectroscopy for Breast Cancer Diagnostics. ( Belkić, D; Belkić, K, 2015) |
| "We investigated PC3 prostate cancer, MCF-7 breast cancer and A375 melanoma cells, and determined that, consistent with previous studies, MRS-detectable levels of phosphocholine decreased significantly in all cell lines (to 63%, 50% and 18% of the control, respectively) following MEK inhibition with U0126." | 1.40 | MR-detectable metabolic consequences of mitogen-activated protein kinase kinase (MEK) inhibition. ( Lodi, A; Ronen, SM; Woods, SM, 2014) |
| "Nude mice bearing human breast cancer flank xenografts were given a systemic injection of CLR1502, and imaging was performed using LUNA (Novadaq Technologies Inc." | 1.40 | Breast cancer imaging using the near-infrared fluorescent agent, CLR1502. ( Grudzinski, J; Jeffery, J; Korb, ML; Rosenthal, EL; Warram, JM; Weichert, J, 2014) |
| "Endocrine resistance in breast cancer remains a major clinical problem and is caused by crosstalk mechanisms of growth factor receptor cascades, such as the erbB and PI3K/AKT pathways." | 1.38 | Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells. ( Block, M; Emons, G; Fister, S; Gründker, C; Günthert, AR; Hemmerlein, B; Kubin, J; Mueller, MD; Wilkens, L, 2012) |
| "Perifosine is an anticancer alkylphospholipid used in clinical trials." | 1.38 | Metabolic consequences of treatment with AKT inhibitor perifosine in breast cancer cells. ( Ronen, SM; Su, JS; Woods, SM, 2012) |
| "Formation of lung and extrapulmonary metastases after intravenous administration of MT3 breast cancer cells was significantly reduced when mice were treated with a single intravenous dose of DIP/OPP-L containing 100nmol lipid 6h before tumour cell inoculation." | 1.35 | Inhibition of breast cancer metastasis by dual liposomes to disturb complex formation. ( Fichtner, I; Wenzel, J; Zeisig, R, 2009) |
| "Breast cancer is still one of the most important tumors among women in industrialized countries." | 1.32 | Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. ( Báñez-Coronel, M; Gutiérrez, R; Lacal, JC; Megías, D; Olmeda, D; Ramírez de Molina, A; Rodríguez-González, A, 2004) |
| "In human MDA-MB-231 breast cancer cells, the maximum inhibition of protein expression ranged from 84% (OPN) to 75% (BSPII) and 70% (ON)." | 1.32 | Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells. ( Adwan, H; Bäuerle, TJ; Berger, MR, 2004) |
| "In patients with breast cancer and skin metastases, topically applied miltefosine solution yields at least partial regression of the lesions in approximately a quarter of patients when used as an adjunct to standard treatment (surgery, radiotherapy, systemic chemotherapy or hormone therapy) or when standard treatments are contraindicated." | 1.30 | Miltefosine: new preparation. Solution for cutaneous application. ( , 1998) |
| "D-19391 was added to the SK-BR-3 breast cancer cell line and HePC to the Molt-4 leukemia cell line in concentrations of, respectively, 18." | 1.30 | Cellular uptake and retention measurements of alkylphosphocholines in the SK-BR-3 breast cancer and Molt-4 leukemia cell line using capillary gas chromatography. ( Brochez, V; De Potter, CR; Diniz, JA; Van den Eeckhout, EG; Van Heuverswyn, D, 1999) |
| " Conventional non-compartmental pharmacokinetic analysis and an elaborate three- and four-compartmental model were used for explaining the experimental data." | 1.30 | Pharmacokinetics of sterically stabilized hexadecylphosphocholine liposomes versus conventional liposomes and free hexadecylphosphocholine in tumor-free and human breast carcinoma bearing mice. ( Arndt, D; Fahr, A; Fichtner, I; Teppke, AD; Zeisig, R, 1999) |
| "Suramin has shown antitumour activity in vitro and in vivo." | 1.29 | The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effects of suramin. ( Lopez Lopez, R; Peters, GJ; Pinedo, HM; van Rijswijk, RE; Wagstaff, J, 1994) |
| "Widespread local recurrence of breast cancer, untreatable by surgery or radiation therapy, can present a serious therapeutic problem predominantly in patients refractory to systemic therapy." | 1.28 | Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients. ( Eibl, H; Hilgard, P; Nagel, G; Peukert, M; Sindermann, H; Unger, C, 1990) |
| " After oral application He-PC was well absorbed from the intestine and metabolized in the liver by phospholipases C and D." | 1.28 | Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo. ( Breiser, A; Damenz, W; Eibl, H; Engel, J; Fleer, EA; Hilgard, P; Kim, DJ; Nagel, G; Unger, C, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (3.61) | 18.7374 |
| 1990's | 27 (32.53) | 18.2507 |
| 2000's | 21 (25.30) | 29.6817 |
| 2010's | 26 (31.33) | 24.3611 |
| 2020's | 6 (7.23) | 2.80 |
| Authors | Studies |
|---|---|
| Santamaría, G | 1 |
| Naude, N | 1 |
| Watson, J | 1 |
| Irvine, J | 1 |
| Lloyd, T | 1 |
| Bennett, I | 1 |
| Galloway, G | 1 |
| Malycha, P | 1 |
| Mountford, C | 1 |
| Yoshida, A | 1 |
| Kitayama, Y | 1 |
| Hayakawa, N | 1 |
| Mizukawa, Y | 1 |
| Nishimura, Y | 1 |
| Takano, E | 1 |
| Sunayama, H | 1 |
| Takeuchi, T | 1 |
| Alrbyawi, H | 1 |
| Boddu, SHS | 1 |
| Poudel, I | 1 |
| Annaji, M | 1 |
| Mita, N | 1 |
| Arnold, RD | 1 |
| Tiwari, AK | 1 |
| Babu, RJ | 1 |
| Wu, Z | 1 |
| Li, S | 1 |
| Cai, Y | 1 |
| Chen, F | 1 |
| Chen, Y | 1 |
| Luo, X | 1 |
| Lv, Z | 1 |
| Wang, S | 1 |
| Zhao, W | 1 |
| He, N | 1 |
| El-Sheridy, NA | 1 |
| El-Moslemany, RM | 1 |
| Ramadan, AA | 1 |
| Helmy, MW | 1 |
| El-Khordagui, LK | 1 |
| Hu, J | 1 |
| Zhuang, W | 1 |
| Ma, B | 1 |
| Su, X | 1 |
| Yu, T | 1 |
| Li, G | 1 |
| Hu, Y | 1 |
| Wang, Y | 1 |
| Shah, T | 3 |
| Krishnamachary, B | 2 |
| Wildes, F | 5 |
| Wijnen, JP | 1 |
| Glunde, K | 7 |
| Bhujwalla, ZM | 8 |
| Ge, D | 1 |
| Gao, J | 1 |
| Han, L | 1 |
| Li, Y | 1 |
| Liu, HH | 1 |
| Yang, WC | 1 |
| Chang, F | 1 |
| Liu, J | 1 |
| Yu, M | 1 |
| Zhao, J | 1 |
| Ward, CS | 2 |
| Eriksson, P | 1 |
| Izquierdo-Garcia, JL | 1 |
| Brandes, AH | 2 |
| Ronen, SM | 8 |
| Esmaeili, M | 1 |
| Bathen, TF | 2 |
| Engebråten, O | 1 |
| Mælandsmo, GM | 2 |
| Gribbestad, IS | 2 |
| Moestue, SA | 2 |
| Mimmi, MC | 1 |
| Finato, N | 1 |
| Pizzolato, G | 1 |
| Beltrami, CA | 1 |
| Fogolari, F | 1 |
| Corazza, A | 1 |
| Esposito, G | 1 |
| Grinde, MT | 1 |
| Skrbo, N | 1 |
| Rødland, EA | 1 |
| Borgan, E | 1 |
| Kristian, A | 1 |
| Sitter, B | 1 |
| Børresen-Dale, AL | 1 |
| Engebraaten, O | 1 |
| Sørlie, T | 1 |
| Marangoni, E | 1 |
| Lodi, A | 1 |
| Woods, SM | 2 |
| Samartzis, EP | 1 |
| Gutsche, K | 1 |
| Dedes, KJ | 1 |
| Fink, D | 1 |
| Stucki, M | 1 |
| Imesch, P | 1 |
| Belkić, D | 1 |
| Belkić, K | 1 |
| Kwok, CW | 1 |
| Treeck, O | 1 |
| Buchholz, S | 1 |
| Seitz, S | 1 |
| Ortmann, O | 1 |
| Engel, JB | 1 |
| Fuhrmann, G | 1 |
| Serio, A | 1 |
| Mazo, M | 1 |
| Nair, R | 1 |
| Stevens, MM | 1 |
| Korb, ML | 1 |
| Warram, JM | 1 |
| Grudzinski, J | 1 |
| Weichert, J | 1 |
| Jeffery, J | 1 |
| Rosenthal, EL | 1 |
| Maria, RM | 1 |
| Altei, WF | 1 |
| Andricopulo, AD | 1 |
| Becceneri, AB | 1 |
| Cominetti, MR | 1 |
| Venâncio, T | 1 |
| Colnago, LA | 1 |
| Holohan, B | 1 |
| Hagiopian, MM | 1 |
| Lai, TP | 1 |
| Huang, E | 1 |
| Friedman, DR | 1 |
| Wright, WE | 1 |
| Shay, JW | 1 |
| Mori, N | 2 |
| Kakkad, S | 3 |
| Jacob, D | 1 |
| Solaiyappan, M | 1 |
| Kim, HJ | 1 |
| Kang, GJ | 1 |
| Kim, EJ | 1 |
| Park, MK | 1 |
| Byun, HJ | 1 |
| Nam, S | 1 |
| Lee, H | 1 |
| Lee, CH | 1 |
| Chakrabandhu, K | 1 |
| Huault, S | 1 |
| Hueber, AO | 1 |
| Wenzel, J | 1 |
| Zeisig, R | 5 |
| Fichtner, I | 6 |
| Takagi, T | 1 |
| Raman, V | 2 |
| Shimada, T | 1 |
| Ueda, M | 1 |
| Jinno, H | 1 |
| Chiba, N | 1 |
| Wada, M | 1 |
| Watanabe, J | 1 |
| Ishihara, K | 1 |
| Kitagawa, Y | 1 |
| Huang, C | 1 |
| Hydo, LM | 1 |
| Liu, S | 1 |
| Miller, RT | 1 |
| Penet, MF | 1 |
| Winnard, PT | 1 |
| Artemov, D | 2 |
| Ackerstaff, E | 2 |
| Gimi, B | 1 |
| Amstalden van Hove, ER | 1 |
| Blackwell, TR | 1 |
| Klinkert, I | 1 |
| Eijkel, GB | 1 |
| Heeren, RM | 1 |
| Guo, JP | 1 |
| Coppola, D | 1 |
| Cheng, JQ | 1 |
| Stasinopoulos, I | 1 |
| Montales, MT | 1 |
| Rahal, OM | 1 |
| Kang, J | 1 |
| Rogers, TJ | 1 |
| Prior, RL | 1 |
| Wu, X | 1 |
| Simmen, RC | 1 |
| Su, JS | 1 |
| Lin, X | 1 |
| Zhang, X | 1 |
| Wang, Q | 1 |
| Li, J | 1 |
| Zhang, P | 1 |
| Zhao, M | 1 |
| Li, X | 1 |
| Block, M | 1 |
| Gründker, C | 1 |
| Fister, S | 1 |
| Kubin, J | 1 |
| Wilkens, L | 1 |
| Mueller, MD | 1 |
| Hemmerlein, B | 1 |
| Emons, G | 1 |
| Günthert, AR | 1 |
| Adwan, H | 1 |
| Bäuerle, TJ | 1 |
| Berger, MR | 3 |
| Jie, C | 1 |
| Ramírez de Molina, A | 2 |
| Báñez-Coronel, M | 1 |
| Gutiérrez, R | 1 |
| Rodríguez-González, A | 1 |
| Olmeda, D | 1 |
| Megías, D | 1 |
| Lacal, JC | 2 |
| Beloueche-Babari, M | 2 |
| Jackson, LE | 3 |
| Al-Saffar, NM | 3 |
| Workman, P | 3 |
| Leach, MO | 4 |
| Kugler, W | 1 |
| Buchholz, F | 1 |
| Köhler, F | 1 |
| Eibl, H | 6 |
| Lakomek, M | 1 |
| Erdlenbruch, B | 1 |
| Troy, H | 1 |
| Madhu, B | 1 |
| Griffiths, JR | 1 |
| Judson, IR | 1 |
| Chung, YL | 1 |
| Eccles, SA | 1 |
| Raynaud, FI | 1 |
| Eliyahu, G | 1 |
| Kreizman, T | 1 |
| Degani, H | 6 |
| Leighl, NB | 1 |
| Dent, S | 1 |
| Clemons, M | 1 |
| Vandenberg, TA | 1 |
| Tozer, R | 1 |
| Warr, DG | 1 |
| Crump, RM | 1 |
| Hedley, D | 1 |
| Pond, GR | 1 |
| Dancey, JE | 1 |
| Moore, MJ | 1 |
| Morse, DL | 1 |
| Raghunand, N | 1 |
| Sadarangani, P | 1 |
| Murthi, S | 1 |
| Job, C | 1 |
| Day, S | 1 |
| Howison, C | 1 |
| Gillies, RJ | 2 |
| Singer, S | 1 |
| Souza, K | 1 |
| Thilly, WG | 1 |
| Lopez Lopez, R | 1 |
| van Rijswijk, RE | 1 |
| Wagstaff, J | 1 |
| Pinedo, HM | 1 |
| Peters, GJ | 1 |
| Naundorf, H | 2 |
| Jungmann, S | 1 |
| Arndt, D | 4 |
| Asongwe, G | 1 |
| Double, JA | 1 |
| Bibby, MC | 2 |
| Bruyneel, EA | 1 |
| Storme, GA | 1 |
| Schallier, DC | 1 |
| Van den Berge, DL | 1 |
| Hilgard, P | 5 |
| Mareel, MM | 1 |
| Colombo, DT | 2 |
| Tran, LK | 2 |
| Reitz, RC | 2 |
| Clive, S | 2 |
| Leonard, RC | 2 |
| Eue, I | 1 |
| Sternberg, B | 1 |
| Safa, O | 1 |
| Parkin, SM | 1 |
| Speck, JJ | 1 |
| Katz-Brull, R | 2 |
| Margalit, R | 1 |
| Bendel, P | 1 |
| Cheng, LL | 1 |
| Chang, IW | 1 |
| Smith, BL | 1 |
| Gonzalez, RG | 1 |
| Stahn, R | 1 |
| Terwogt, JM | 1 |
| Mandjes, IA | 1 |
| Sindermann, H | 5 |
| Beijnen, JH | 1 |
| ten Bokkel Huinink, WW | 1 |
| Aboagye, EO | 1 |
| Chacko, VP | 1 |
| Mendola, CE | 1 |
| Backer, JM | 1 |
| Brochez, V | 1 |
| Van Heuverswyn, D | 1 |
| Diniz, JA | 1 |
| De Potter, CR | 1 |
| Van den Eeckhout, EG | 1 |
| Gardiner, J | 1 |
| Teppke, AD | 1 |
| Fahr, A | 1 |
| Smorenburg, CH | 1 |
| Seynaeve, C | 1 |
| Bontenbal, M | 1 |
| Planting, AS | 1 |
| Verweij, J | 1 |
| Moĭseenko, VM | 1 |
| Orlova, RV | 1 |
| Ermakova, NA | 1 |
| Protsenko, SA | 1 |
| Rybczynska, M | 1 |
| Liu, R | 1 |
| Lu, P | 1 |
| Sharom, FJ | 1 |
| Steinfels, E | 1 |
| Pietro, AD | 1 |
| Spitaler, M | 1 |
| Grunicke, H | 1 |
| Hofmann, J | 1 |
| Leonard, R | 1 |
| Hardy, J | 1 |
| van Tienhoven, G | 1 |
| Houston, S | 1 |
| Simmonds, P | 1 |
| David, M | 1 |
| Mansi, J | 1 |
| Seger, D | 1 |
| Rivenson-Segal, D | 1 |
| Rushkin, E | 3 |
| Haberkorn, U | 1 |
| Reinhardt, M | 2 |
| Strauss, LG | 1 |
| Oberdorfer, F | 1 |
| Altmann, A | 1 |
| Wallich, R | 1 |
| Dimitrakopoulou, A | 1 |
| van Kaick, G | 1 |
| Unger, C | 5 |
| Peukert, M | 3 |
| Engel, J | 3 |
| Rewasowa, EC | 1 |
| Büttner, B | 1 |
| Becker, M | 1 |
| Görlich, M | 1 |
| Yanapirut, P | 1 |
| Schmähl, D | 1 |
| Smith, TA | 1 |
| Glaholm, J | 1 |
| Machin, L | 1 |
| Collins, DJ | 1 |
| Payne, GS | 1 |
| McCready, VR | 1 |
| Nagel, G | 2 |
| Neeman, M | 1 |
| Damenz, W | 1 |
| Fleer, EA | 1 |
| Kim, DJ | 1 |
| Breiser, A | 2 |
| von Heyden, HW | 1 |
| Nagel, GA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2 Study Of Perifosine In Metastatic Or Advanced Breast Cancer[NCT00054145] | Phase 2 | 0 participants | Interventional | 2003-06-30 | Completed | ||
| Fluorescent Nanoparticles Conjugated Long-acting Somatostatin Analog for Potent Suppression and Bioimaging Breast Cancer[NCT04138342] | Phase 1 | 30 participants (Anticipated) | Interventional | 2019-09-15 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for phosphorylcholine and Breast Cancer
| Article | Year |
|---|---|
Choline phospholipid metabolism: a target in cancer cells?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Breast Neoplasms; Choline Kinase; En | 2003 |
Hexadecylphosphocholine: a new and selective antitumor drug.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Drug Screening Assays, Antitumor; Female; Humans; | 1990 |
6 trials available for phosphorylcholine and Breast Cancer
| Article | Year |
|---|---|
A Phase 2 study of perifosine in advanced or metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Kaplan-Meier Estimate; Middle | 2008 |
Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Dr | 1999 |
Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Br | 1999 |
Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients.
Topics: Administration, Topical; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Middl | 2000 |
[Treatment with Miltex for metastatic skin lesions in breast cancer] .
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Middle Aged; Phosphorylcholine; Skin | 2000 |
Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Do | 2001 |
75 other studies available for phosphorylcholine and Breast Cancer
| Article | Year |
|---|---|
Breast Tissue Chemistry Measured In Vivo In Healthy Women Correlate with Breast Density and Breast Cancer Risk.
Topics: Breast Density; Breast Neoplasms; Choline; Female; Glucose; Glutamates; Glutamine; Humans; Lipids; M | 2022 |
Biocompatible polymer-modified gold nanocomposites of different shapes as radiation sensitizers.
Topics: Breast Neoplasms; Female; Gold; Humans; Nanocomposites; Phosphorylcholine; Polymers; Polymethacrylic | 2022 |
Cardiolipin for Enhanced Cellular Uptake and Cytotoxicity of Thermosensitive Liposome-Encapsulated Daunorubicin toward Breast Cancer Cell Lines.
Topics: Breast Neoplasms; Cardiolipins; Cholesterol; Daunorubicin; Female; Humans; Lipid Bilayers; Liposomes | 2022 |
Synergistic action of doxorubicin and 7-Ethyl-10-hydroxycamptothecin polyphosphorylcholine polymer prodrug.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Surviva | 2020 |
MicroRNA analysis of NCI-60 human cancer cells indicates that miR-720 and miR-887 are potential therapeutic biomarkers for breast cancer.
Topics: Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Databases, | 2020 |
Enhancing the
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Survival; Chemistry, Pharmaceutica | 2021 |
Redox-Responsive Biomimetic Polymeric Micelle for Simultaneous Anticancer Drug Delivery and Aggregation-Induced Emission Active Imaging.
Topics: Animals; Antineoplastic Agents; Biomimetic Materials; Biomimetics; Breast Neoplasms; Cell Line, Tumo | 2018 |
Molecular causes of elevated phosphoethanolamine in breast and pancreatic cancer cells.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Down-Regulation; Epithelial Cells; Ethan | 2018 |
Novel effects of sphingosylphosphorylcholine on the apoptosis of breast cancer via autophagy/AKT/p38 and JNK signaling.
Topics: Apoptosis; Autophagy; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Female; Gene Expression Reg | 2019 |
HDAC inhibition induces increased choline uptake and elevated phosphocholine levels in MCF7 breast cancer cells.
Topics: Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Choline; Enzyme Activation; Fema | 2013 |
Quantitative (31)P HR-MAS MR spectroscopy for detection of response to PI3K/mTOR inhibition in breast cancer xenografts.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Breast Neoplasms; Ethanolamine | 2014 |
Absolute quantification of choline-related biomarkers in breast cancer biopsies by liquid chromatography electrospray ionization mass spectrometry.
Topics: Acetonitriles; Biomarkers, Tumor; Biopsy; Breast; Breast Neoplasms; Carcinoma, Ductal, Breast; Carci | 2013 |
Interplay of choline metabolites and genes in patient-derived breast cancer xenografts.
Topics: Animals; Breast Neoplasms; Choline; Choline Kinase; Female; Gene Expression; Gene Expression Profili | 2014 |
MR-detectable metabolic consequences of mitogen-activated protein kinase kinase (MEK) inhibition.
Topics: AMP-Activated Protein Kinases; Breast Neoplasms; Butadienes; Cell Line, Tumor; Glycolysis; Humans; M | 2014 |
Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition.
Topics: Aminopyridines; Apoptosis; Breast Neoplasms; DNA-Binding Proteins; Female; Gene Knockdown Techniques | 2014 |
Proof-of-the-Concept Study on Mathematically Optimized Magnetic Resonance Spectroscopy for Breast Cancer Diagnostics.
Topics: Breast Neoplasms; Female; Fourier Analysis; Humans; Magnetic Resonance Spectroscopy; Phosphorylcholi | 2015 |
Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC).
Topics: Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 2015 |
Active loading into extracellular vesicles significantly improves the cellular uptake and photodynamic effect of porphyrins.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell-Derived Microparticles; Chemistry, Pharmaceutical; Choleste | 2015 |
Breast cancer imaging using the near-infrared fluorescent agent, CLR1502.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Diagnostic Imaging; Female; Fluorescent Dyes; Humans; I | 2014 |
Characterization of metabolic profile of intact non-tumor and tumor breast cells by high-resolution magic angle spinning nuclear magnetic resonance spectroscopy.
Topics: Acetone; Biomarkers; Brazil; Breast; Breast Neoplasms; Cell Line; Cell Line, Tumor; Ethanol; Female; | 2015 |
Perifosine as a potential novel anti-telomerase therapy.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; | 2015 |
Choline kinase-α protein and phosphatidylcholine but not phosphocholine are required for breast cancer cell survival.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Survival; Choline Kinase; Humans; Phosphatidylcholines; Pho | 2015 |
Novel effects of sphingosylphosphorylcholine on invasion of breast cancer: Involvement of matrix metalloproteinase-3 secretion leading to WNT activation.
Topics: Breast Neoplasms; Caproates; Cell Line, Tumor; Female; Flavonoids; Gene Silencing; Humans; Matrix Me | 2016 |
Distinctive molecular signaling in triple-negative breast cancer cell death triggered by hexadecylphosphocholine (miltefosine).
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Fas Ligand Protein; fas Recept | 2008 |
Inhibition of breast cancer metastasis by dual liposomes to disturb complex formation.
Topics: Animals; Antineoplastic Agents; Blood Platelets; Breast Neoplasms; Cell Line, Tumor; Dipyridamole; D | 2009 |
Noninvasive detection of lentiviral-mediated choline kinase targeting in a human breast cancer xenograft.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Choline Kinase; Down-Regulation; Female; Genetic Therap | 2009 |
Development of targeted therapy with paclitaxel incorporated into EGF-conjugated nanoparticles.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Delivery Systems; Epidermal Growt | 2009 |
Activation of choline kinase by extracellular Ca2+ is Ca(2+)-sensing receptor, Galpha12 and Rho-dependent in breast cancer cells.
Topics: Breast Neoplasms; Calcium; Cell Line; Cell Line, Tumor; Choline Kinase; Enzyme Activation; Female; G | 2009 |
Choline kinase overexpression increases invasiveness and drug resistance of human breast cancer cells.
Topics: Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Choline Kinase; Drug Resistance, Neoplasm; Fe | 2010 |
17-allyamino-17-demethoxygeldanamycin treatment results in a magnetic resonance spectroscopy-detectable elevation in choline-containing metabolites associated with increased expression of choline transporter SLC44A1 and phospholipase A2.
Topics: Antigens, CD; Antineoplastic Agents; Benzoquinones; Biological Transport; Biomarkers, Tumor; Breast | 2010 |
Multimodal mass spectrometric imaging of small molecules reveals distinct spatio-molecular signatures in differentially metastatic breast tumor models.
Topics: Animals; Breast Neoplasms; Choline; Female; Glycerylphosphorylcholine; Humans; Magnetic Resonance Im | 2010 |
IKBKE protein activates Akt independent of phosphatidylinositol 3-kinase/PDK1/mTORC2 and the pleckstrin homology domain to sustain malignant transformation.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Animals; Breast Neoplasms; Cell Line, Tumor; Cell Tran | 2011 |
Noninvasive imaging identifies new roles for cyclooxygenase-2 in choline and lipid metabolism of human breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Choline; Choline Kinase; Cyclooxygenase 2; Female; Gene Knockdow | 2012 |
Repression of mammosphere formation of human breast cancer cells by soy isoflavone genistein and blueberry polyphenolic acids suggests diet-mediated targeting of cancer stem-like/progenitor cells.
Topics: Animals; Blueberry Plants; Breast Neoplasms; CD24 Antigen; Cell Line, Tumor; Female; Genistein; Huma | 2012 |
Metabolic consequences of treatment with AKT inhibitor perifosine in breast cancer cells.
Topics: Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Choline; Choline Kinase; Choline-Phosphate Cytidylyl | 2012 |
Perifosine downregulates MDR1 gene expression and reverses multidrug-resistant phenotype by inhibiting PI3K/Akt/NF-κB signaling pathway in a human breast cancer cell line.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamil | 2012 |
Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Class I Ph | 2012 |
Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Down-Regulation; Drug Therapy, Combination; Female; Gen | 2004 |
Molecular causes of the aberrant choline phospholipid metabolism in breast cancer.
Topics: Breast Neoplasms; Carbon Isotopes; Cell Line, Tumor; Cell Membrane; Choline; Choline Kinase; Humans; | 2004 |
Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression.
Topics: Animals; Breast Neoplasms; Cell Division; Choline Kinase; Disease Progression; Enzyme Activation; En | 2004 |
Magnetic resonance spectroscopy monitoring of mitogen-activated protein kinase signaling inhibition.
Topics: Biomarkers, Tumor; Breast Neoplasms; Butadienes; Cell Line, Tumor; Colorectal Neoplasms; Enzyme Inhi | 2005 |
Downregulation of Apaf-1 and caspase-3 by RNA interference in human glioma cells: consequences for erucylphosphocholine-induced apoptosis.
Topics: Apoptosis; Apoptotic Protease-Activating Factor 1; BH3 Interacting Domain Death Agonist Protein; Bre | 2005 |
Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Butanes; Carcinoma; Choline Kin | 2006 |
Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells.
Topics: Androstadienes; Breast Neoplasms; Cell Extracts; Chromones; Enzyme Inhibitors; Female; Glycerylphosp | 2006 |
Phosphocholine as a biomarker of breast cancer: molecular and biochemical studies.
Topics: Biomarkers, Tumor; Breast; Breast Neoplasms; Choline Kinase; Humans; Membrane Transport Proteins; Or | 2007 |
Response of choline metabolites to docetaxel therapy is quantified in vivo by localized (31)P MRS of human breast cancer xenografts and in vitro by high-resolution (31)P NMR spectroscopy of cell extracts.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival | 2007 |
Pyruvate utilization, phosphocholine and adenosine triphosphate (ATP) are markers of human breast tumor progression: a 31P- and 13C-nuclear magnetic resonance (NMR) spectroscopy study.
Topics: Adenosine Triphosphate; Biomarkers; Breast Neoplasms; Citric Acid Cycle; Female; Humans; Magnetic Re | 1995 |
The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effects of suramin.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Divisi | 1994 |
Antineoplastic activity of alkylphosphocholines (APC) in human breast carcinomas in vivo and in vitro; use of liposomes.
Topics: Administration, Oral; Adult; Aged; Animals; Antineoplastic Agents; Breast Neoplasms; Dose-Response R | 1994 |
Evidence for abrogation of oncogene-induced radioresistance of mammary cancer cells by hexadecylphosphocholine in vitro.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Survival; Female; Gene Expression Regulation, Neoplast | 1993 |
The effects of hexadecylphosphocholine (HPC) a mixture of alkylphosphocholines (APC) and different dietary oils on the growth of a human mammary tumor.
Topics: Animals; Breast Neoplasms; Corn Oil; Dietary Fats, Unsaturated; Dinoprostone; Fish Oils; Humans; Mic | 1993 |
Miltefosine in recurrent cutaneous breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Phosphorylcholi | 1997 |
Antineoplastic activity of sterically stabilized alkylphosphocholine liposomes in human breast carcinomas.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Survival; Cholesterol; Ethanol | 1997 |
IL-1 gene expression in human mammary tumour xenografts after treatment with hexadecylphosphocholine.
Topics: Animals; Antigens, CD; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Female; Gene Expre | 1997 |
Comparison of hexadecylphosphocholine with fish oil as an antitumor agent.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Dinoprostone; Docosahexaenoic Acids; Drug Combinat | 1997 |
Choline metabolism in breast cancer; 2H-, 13C- and 31P-NMR studies of cells and tumors.
Topics: Animals; Breast Neoplasms; Carbon Isotopes; Choline; Deuterium; Female; Humans; Male; Mice; Mice, Nu | 1998 |
Evaluating human breast ductal carcinomas with high-resolution magic-angle spinning proton magnetic resonance spectroscopy.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Diag | 1998 |
Physical properties and pharmacological activity in vitro and in vivo of optimised liposomes prepared from a new cancerostatic alkylphospholipid.
Topics: Animals; Breast Neoplasms; Cell Division; Female; Humans; Liposomes; Metallothionein 3; Mice; Mice, | 1998 |
Miltefosine: new preparation. Solution for cutaneous application.
Topics: Administration, Cutaneous; Antineoplastic Agents; Blood Cell Count; Breast Neoplasms; Clinical Trial | 1998 |
Nm23-transfected MDA-MB-435 human breast carcinoma cells form tumors with altered phospholipid metabolism and pH: a 31P nuclear magnetic resonance study in vivo and in vitro.
Topics: Animals; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Ethanolamines; Female; Genetic Vectors; Gly | 1999 |
Cellular uptake and retention measurements of alkylphosphocholines in the SK-BR-3 breast cancer and Molt-4 leukemia cell line using capillary gas chromatography.
Topics: Antineoplastic Agents; Breast Neoplasms; Chromatography, Gas; Humans; Leukemia; Phosphorylcholine; R | 1999 |
Pharmacokinetics of sterically stabilized hexadecylphosphocholine liposomes versus conventional liposomes and free hexadecylphosphocholine in tumor-free and human breast carcinoma bearing mice.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Breast Neoplasms; Chemistry, Pharmaceutical; Disea | 1999 |
MDR1 causes resistance to the antitumour drug miltefosine.
Topics: Adenocarcinoma; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Ca | 2001 |
Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis.
Topics: Betaine; Biomarkers, Tumor; Breast; Breast Neoplasms; Carbon Isotopes; Choline; Epithelial Cells; Hu | 2002 |
Metabolic design of combination therapy: use of enhanced fluorodeoxyglucose uptake caused by chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chromatogra | 1992 |
Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; | 1992 |
Characterization of two human mammary carcinomas, MT-1 and MT-3, suitable for in vivo testing of ether lipids and their derivatives.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Division; Drug Screening Assays, A | 1992 |
Lipid metabolism in large T47D human breast cancer spheroids: 31P- and 13C-NMR studies of choline and ethanolamine uptake.
Topics: Breast Neoplasms; Cell Division; Choline; Ethanolamine; Ethanolamines; Humans; Magnetic Resonance Sp | 1992 |
Lipid metabolism in T47D human breast cancer cells: 31P and 13C-NMR studies of choline and ethanolamine uptake.
Topics: Breast Neoplasms; Choline; Choline-Phosphate Cytidylyltransferase; Ethanolamine; Ethanolamines; Glyc | 1991 |
In vitro investigations on the antineoplastic effect of hexadecylphosphocholine.
Topics: Animals; Antineoplastic Agents; Bone Marrow Cells; Breast Neoplasms; Colony-Forming Units Assay; Hum | 1991 |
A comparison of in vivo and in vitro 31P NMR spectra from human breast tumours: variations in phospholipid metabolism.
Topics: Breast Neoplasms; Ethanolamines; Glycerylphosphorylcholine; Humans; Magnetic Resonance Spectroscopy; | 1991 |
Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Dr | 1990 |
Metabolic studies of estrogen- and tamoxifen-treated human breast cancer cells by nuclear magnetic resonance spectroscopy.
Topics: Breast Neoplasms; Cell Line; Estradiol; Glucose; Glutamates; Glutamic Acid; Humans; Lactates; Lactic | 1989 |
Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Choline; Drug Screening Assays, Antitumor; Female; | 1989 |
Hexadecylphosphocholine (D 18506) in the topical treatment of skin metastases: a phase-I trial.
Topics: Administration, Topical; Breast Neoplasms; Choline; Drug Evaluation; Female; Humans; Neoplasm Recurr | 1988 |